Saturday 17 October 2026
Export NRIX’s income statement to Excel — free account
Nurix Therapeutics, Inc.
NRIX Healthcare Biotechnology
Nurix Therapeutics, Inc.’s revenue for fiscal 2025 (year ended November 2025) was $84.0 million, up 54.0% from fiscal 2024. In the quarter to August 2026, revenue grew 8,426.3%, EPS grew 578.5% and free cash flow grew 1,122.1%, each against the same quarter a year earlier.
24.42
0.53
−2.12%
Follow NRIX
| Older periods | Nov '25 | Feb '26 | May '26 | Aug '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
0.00 | 0.00 | 0.00 | 10.28 |
P/S ratio |
17.45 | 24.24 | 52.54 | 4.10 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 7.78 | |
P/Operating CF |
(21.61) | (24.20) | (20.00) | 4.67 | |
P/B ratio |
2.72 | 3.62 | 4.80 | 2.97 | |
Price to Tangible BV |
2.72 | 3.62 | 4.80 | 2.97 | |
EV/Sales |
10.39 | 16.71 | 40.48 | 2.60 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 6.19 | |
EV/Operating CF |
(3.50) | (4.61) | (5.07) | 4.82 | |
EV/FCF |
(3.31) | (4.41) | (4.89) | 4.94 | |
Quick Ratio |
6.86 | 5.86 | 6.16 | 8.17 | |
Current Ratio |
7.02 | 6.01 | 6.34 | 8.44 | |
Net Debt/EBITDA |
6.68 | 6.09 | 4.91 | (1.86) | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.12 | 0.11 | 0.07 | 0.82 | |
Operating CF/Net income |
0.87 | 0.82 | 1.08 | 1.12 | |
Capex/Depreciation |
0.90 | (0.28) | (0.50) | (0.39) | |
Research and Development Expense of Revenue |
611.50% | 1,345.76% | 969.29% | 11.78% | |
Selling, General and Administrative Expense of Revenue |
100.52% | 233.69% | 172.44% | 5.10% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
66.92% | 150.42% | 125.93% | 1.60% | |
Graham Net Nets |
0.31 | 0.23 | 0.17 | 0.30 | |
Graham Number |
0.00 | 0.00 | 0.00 | 22.13 | |
Earnings Yield |
(17.98%) | (19.99%) | (19.84%) | 9.73% | |
Free Cash Flow Yield |
(17.98%) | (15.62%) | (15.76%) | 12.86% | |
Revenue per Share |
0.16 | 0.06 | 0.08 | 6.03 | |
Operating CF per Share |
(0.78) | (0.65) | (0.87) | 5.52 | |
Capex per Share |
(0.06) | (0.01) | (0.02) | (0.01) | |
Free Cash Flow per Share |
(0.84) | (0.66) | (0.89) | 5.51 | |
Cash per Share |
6.84 | 4.91 | 3.99 | 9.40 | |
Shareholders Equity per Share |
6.22 | 4.37 | 3.62 | 8.68 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
6.22 | 4.37 | 3.62 | 8.68 | |
Free Cash Flow |
(72.96) | (72.96) | (98.51) | 614.24 | |
Working Capital |
520.35 | 462.20 | 384.46 | 972.95 | |
Capital Expenditures |
(5.13) | (1.04) | (1.94) | (1.39) | |
Net Current Asset Value |
457.43 | 399.16 | 323.57 | 876.71 | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 6.31 | |
Capex to Sales |
0.38 | 0.17 | 0.21 | 0.00 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 9.93 | |
| Other line items | |||||
Average Receivables |
— | — | — | 10.60 | |
Average Payables |
11.35 | 9.35 | 9.08 | 20.80 | |
Average Assets |
678.74 | 625.59 | 563.55 | 858.89 | |
Average Common Equity |
532.87 | 480.91 | 425.12 | 670.28 |
Columns are period end dates · fundamentals updated 15 Oct 2026